Product Reports Resources Pricing Login Book a demo

AxoGen

Biotech & Life Sciences · Alachua, United States · Founded 2002 · IPO 2013

Developing technologies for peripheral nerve regeneration and repair MoreLess

AxoGen, Inc. (NASDAQ: AXGN) operates as a specialized medical technology firm focused on developing and commercializing surgical solutions for peripheral nerve repair. The company was founded in 2002 by Jamie Grooms, John P. Engels, and University of Florida neuroscientist David Muir, stemming from research conducted at the University of Florida and the University of Texas at Austin. This research aimed to address the limitations of traditional nerve repair, which often required a second surgery and could result in lasting damage. AxoGen was established in Alachua, Florida, within the Sid Martin Biotechnology Incubator, to bring these new technologies to market. A significant milestone was achieved in 2013 when the company went public with an initial public offering (IPO), raising $18 million.

The company’s business model centers on the direct sale of its product portfolio to hospitals and surgical centers. This portfolio targets a market opportunity estimated to exceed $2.7 billion in the U.S. for peripheral nerve damage repair. The client base primarily consists of reconstructive plastic surgeons, hand surgeons, and oral and maxillofacial surgeons. Revenue is generated directly from the sale of its products, with reported revenues of $110.2 million from its direct sales force in 2023. For fiscal year 2024, the company projects revenues between $176.0 million and $179.0 million.

AxoGen offers a comprehensive suite of products for peripheral nerve repair. Its cornerstone product, the Avance® Nerve Graft, is a processed human nerve allograft for bridging gaps in severed nerves, eliminating the need for a second surgical site. Other key products include the Axoguard Nerve Connector®, a coaptation aid for tensionless nerve repair; the Axoguard Nerve Protector®, which wraps and shields injured nerves; and the Axoguard Nerve Cap®, designed to protect nerve ends and reduce neuroma formation. These products are designed to provide surgeons with clinically proven and economically effective solutions to restore nerve function and improve patients' quality of life.

Keywords: peripheral nerve repair, nerve regeneration, surgical solutions, medical technology, Avance Nerve Graft, nerve allograft, Axoguard, reconstructive surgery, hand surgery, oral surgery, nerve damage, tissue grafts, regenerative medicine, neurosurgery, surgical devices, neuroma treatment, nerve protection, biotechnology, medical devices, AXGN

Valuation $2.18B
Revenue $280M
EBITDA $33M
Total funding $10–50M

Talent graph

AxoGen's talent

Book a demo to see the people
Team profiled 25 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on AxoGen's cap table

Sourced from Dealroom's funding and investor records.

Series A 5 investors entered at this stage
DeNovo Ventures
Springboard Capital
Essex Woodlands Health Ventures
Accuitive Medical Ventures
Cardinal Partners
Series B+ 2 investors entered at this stage
PDL Biopharma
Armentum Partners

Global footprint

Where AxoGen has talent and traffic

Workforce by country
3 countries with
team presence
🇺🇸 United States99.3%
🇩🇪 Germany0.5%
🇨🇦 Canada0.2%
3 countries shown
Web traffic by country
4K monthly visits
across markets
🏳️ Korea72.5%
🏳️ Republic of27.5%
🇺🇸 United States2.5%
🇮🇩 Indonesia0%
Top 4 markets shown

Patent intelligence

$62M patent portfolio · 64 active families

Estimated portfolio value
$62M
2.8% of market cap · comparable to top peer Gyroscope Therapeutics ($46M)
64 active patent families
Where AxoGen innovates AnatomyBarbed sutureBiologyBiomedical engineeringGeneral surgery

Where AxoGen concentrates vs peers

Each axis is a top-10 topic across AxoGen and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about AxoGen

An AI-synthesized read of the highest-engagement posts about AxoGen on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AxoGen on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.